ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
61,393.89
0.34%
S&P 500
5,203.92
0.31%
Dow Jones
39,249.15
0.49%
US Dollar vs Yen
155.5205
0.06%
Brent Oil
83.715
0.19%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Sangamo Therapeutics Inc (SGMO)

  7. Sangamo Therapeutics Inc (SGMO) ニュース

SGMO

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:SGMO
日付受信時刻ニュースソース見出しコード企業名
2024/05/0921 : 05Business WireSangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome EditingNASDAQ:SGMOSangamo Therapeutics Inc
2024/05/0305 : 15Business WireSangamo Therapeutics Announces First Quarter 2024 Conference Call and WebcastNASDAQ:SGMOSangamo Therapeutics Inc
2024/04/2305 : 35Business WireSangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)NASDAQ:SGMOSangamo Therapeutics Inc
2024/03/2221 : 05Business WireSangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct OfferingNASDAQ:SGMOSangamo Therapeutics Inc
2024/03/1321 : 05Business WireSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:SGMOSangamo Therapeutics Inc
2024/03/1321 : 01Business WireSangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPsNASDAQ:SGMOSangamo Therapeutics Inc
2024/03/1307 : 30Business WireSangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and WebcastNASDAQ:SGMOSangamo Therapeutics Inc
2024/02/2807 : 14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
2024/02/2807 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
2024/02/2807 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
2024/02/2807 : 12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
2024/02/2807 : 11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
2024/02/1222 : 05Business WireSangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry DiseaseNASDAQ:SGMOSangamo Therapeutics Inc
2024/02/0706 : 35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGMOSangamo Therapeutics Inc
2024/02/0608 : 01Business WireSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety ProfileNASDAQ:SGMOSangamo Therapeutics Inc
2024/01/2701 : 49Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SGMOSangamo Therapeutics Inc
2024/01/2506 : 42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
2024/01/2506 : 42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
2024/01/2506 : 41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
2024/01/2506 : 40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
2024/01/2506 : 39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
2024/01/2007 : 09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGMOSangamo Therapeutics Inc
2023/12/1321 : 55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGMOSangamo Therapeutics Inc
2023/11/2906 : 20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
2023/11/2906 : 19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
2023/11/2906 : 19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
2023/11/2906 : 18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
2023/11/2906 : 17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
2023/11/2906 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
2023/11/2906 : 15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SGMO

最近閲覧した銘柄

CCOM
US30
US 30
NYSE
VZ
Verizon Communications
USOTC
BASFY
BASF (QX)
NASDAQ
NVDA
NVIDIA
NASDAQ
AAPL
Apple
USOTC
RHHBY
Roche (QX)
NYSE
MRK
Merck
AMEX
XLE
Energy Select Sector SPDR
NYSE
CVX
Chevron
NYSE
AXP
American Express
NASDAQ
GOOGL
Alphabet
FX
USDGBP
US Dollar vs Sterling
SPI
SP500
S&P 500
CCOM
SILVER
SILVER
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
MCD
McDonalds
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有